7436 results
Cited 16 times since 2018 (2.5 per year)
source: EuropePMC
Cardiovascular research,
Volume 114, Issue 14, 1 1 2018, Pages 1848-1859
Generation and primary characterization of iAM-1, a versatile new line of conditionally immortalized atrial myocytes with preserved cardiomyogenic differentiation capacity.
Liu J, Volkers L, Jangsangthong W, Bart CI, Engels MC, Zhou G, Schalij MJ, Ypey DL, Pijnappels DA, de Vries AAF
Aims: The generation of homogeneous cardiomyocyte populations from fresh tissue or stem cells is laborious and costly. A potential solution to this problem would be to establish lines of immortalized cardiomyocytes. However, as proliferation and (terminal) differentiation of cardiomyocytes are mutually exclusive processes, their permanent immortalization causes loss of electrical and mechanical functions. We therefore aimed at developing conditionally immortalized atrial myocyte (iAM) lines allo...
Abstract
Cited 15 times since 2018 (2.4 per year)
source: EuropePMC
Nature genetics,
Volume 50, Issue 12, 1 1 2018, Pages 1755
Publisher Correction: Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits.
Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, Ntritsos G, Dimou N, Cabrera CP, Karaman I, Ng FL, Evangelou M, Witkowska K, Tzanis E, Hellwege JN, Giri A, Velez Edwards DR, Sun YV, Cho K, Gaziano JM, Wilson PWF, Tsao PS, Kovesdy CP, Esko T, Mägi R, Milani L, Almgren P, Boutin T, Debette S, Ding J, Giulianini F, Holliday EG, Jackson AU, Li-Gao R, Lin WY, Luan J, Mangino M, Oldmeadow C, Prins BP, Qian Y, Sargurupremraj M, Shah N, Surendran P, Thériault S, Verweij N, Willems SM, Zhao JH, Amouyel P, Connell J, de Mutsert R, Doney ASF, Farrall M, Menni C, Morris AD, Noordam R, Paré G, Poulter NR, Shields DC, Stanton A, Thom S, Abecasis G, Amin N, Arking DE, Ayers KL, Barbieri CM, Batini C, Bis JC, Blake T, Bochud M, Boehnke M, Boerwinkle E, Boomsma DI, Bottinger EP, Braund PS, Brumat M, Campbell A, Campbell H, Chakravarti A, Chambers JC, Chauhan G, Ciullo M, Cocca M, Collins F, Cordell HJ, Davies G, de Borst MH, de Geus EJ, Deary IJ, Deelen J, Del Greco M F, Demirkale CY, Dörr M, Ehret GB, El
In the version of this article originally published, the name of author Martin H. de Borst was coded incorrectly in the XML. The error has now been corrected in the HTML version of the paper.
Abstract
Cited 4 times since 2018 (0.6 per year)
source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Volume 20, Issue 12, 1 1 2018, Pages 1989-1996
Electrical latency predicts the optimal left ventricular endocardial pacing site: results from a multicentre international registry.
Sieniewicz BJ, Behar JM, Sohal M, Gould J, Claridge S, Porter B, Niederer S, Gamble JHP, Betts TR, Jais P, Derval N, Spragg DD, Steendijk P, van Gelder BM, Bracke FA, Rinaldi CA
Aims: The optimal site for biventricular endocardial (BIVENDO) pacing remains undefined. Acute haemodynamic response (AHR) is reproducible marker of left ventricular (LV) contractility, best expressed as the change in the maximum rate of LV pressure (LV-dp/dtmax), from a baseline state. We examined the relationship between factors known to impact LV contractility, whilst delivering BIVENDO pacing at a variety of LV endocardial (LVENDO) locations. Methods and results: We compiled a registry of ac...
Abstract
Cited 21 times since 2018 (3.3 per year)
source: EuropePMC
The Journal of clinical endocrinology and metabolism,
Volume 103, Issue 12, 1 1 2018, Pages 4569-4579
Blood Metabolomic Measures Associate With Present and Future Glycemic Control in Type 2 Diabetes.
't Hart LM, Vogelzangs N, Mook-Kanamori DO, Brahimaj A, Nano J, van der Heijden AAWA, Willems van Dijk K, Slieker RC, Steyerberg EW, Ikram MA, Beekman M, Boomsma DI, van Duijn CM, Slagboom PE, Stehouwer CDA, Schalkwijk CG, Arts ICW, Dekker JM, Dehghan A, Muka T, van der Kallen CJH, Nijpels G, van Greevenbroek MMJ
Objective: We studied whether blood metabolomic measures in people with type 2 diabetes (T2D) are associated with insufficient glycemic control and whether this association is influenced differentially by various diabetes drugs. We then tested whether the same metabolomic profiles were associated with the initiation of insulin therapy. Methods: A total of 162 metabolomic measures were analyzed using a nuclear magnetic resonance-based method in people with T2D from four cohort studies (n = 2641)...
Abstract
Cited 1 times since 2018 (0.2 per year)
source: EuropePMC
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Volume 54, Issue 6, 1 1 2018, Pages 1147-1148
Off-pump mitral valve repair: is less really more?
Tomšic A, Klautz RJM, Palmen M
Abstract
Cited 3 times since 2018 (0.5 per year)
source: EuropePMC
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Volume 25, Issue 7, 30 5 2018, Pages 1692-1698
A comparison of response in the presence or absence of a delay in induction therapy with bortezomib, lenalidomide, and dexamethasone.
Schepers AJ, Jones AR, Reeves BN, Tuchman SA, Bates JS
Purpose: Lenalidomide, bortezomib, and dexamethasone (RVd) has emerged as a preferred induction therapy in multiple myeloma (MM) in the United States. Due to lenalidomide's teratogenic risk, patients and prescribers must comply with a risk evaluation and mitigation strategy (REMS) program. The REMS program limits dispensing to certain third-party specialty pharmacies, whose average prescription fill times are longer than in-house specialty pharmacies. In practice, a delay in procurement of...
Abstract
Cited 8 times since 2018 (1.3 per year)
source: Scopus
European journal of preventive cardiology,
Volume 26, Issue 6, 28 4 2018, Pages 606-608
BENEFIT for all: An ecosystem to facilitate sustained healthy living and reduce the burden of cardiovascular disease.
Keesman M, Janssen V, Kemps H, Hollander M, Reimer WSO, Gemert-Pijnen LV, Hoes A, Kraaij W, Chavannes N, Atsma D, Kraaijenhagen R, Evers A, BENEFIT consortium
Abstract
Cited 2 times since 2018 (0.3 per year)
source: EuropePMC
PloS one,
Volume 13, Issue 11, 27 4 2018, Pages e0207943
Qualitative evaluation of coronary atherosclerosis in a large cohort of young and middle-aged Dutch tissue donors implies that coronary thrombo-embolic manifestations are stochastic.
Lindeman JH, Hulsbos L, van den Bogaerdt AJ, Geerts M, van Gool AJ, Hamming JF, van Dijk RA, Schaapherder AF
Background and aims: With the intention to gain support for the hypothesis that incident ischemic complications of atherosclerotic disease involve a stochastic aspect, we performed a histological, qualitative evaluation of the epidemiology of coronary atherosclerotic disease in a cohort of aortic valve donors. Patients and methods: Donors (n = 695, median age 54, range 11-65 years) were dichotomized into a non-cardiovascular (non-CVD) and a cardiovascular disease death (CVD) group. Consecutive 5...
Abstract
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology,
Volume 26, Issue 1, 20 3 2018, Pages 76-85
Multimodality imaging: Bird's eye view from The European Society of Cardiology Congress 2018 Munich, August 25-29, 2018.
Delgado V, Bucciarelli-Ducci C, Gaemperli O, Maurovich-Horvat P, Bax JJ
At the European Society of Cardiology (ESC) congress of this year 2018, held in Munich from August 25th to 29th, 4594 abstracts were presented. Of those, 423 (10.8%) belonged to an imaging category. Experts in echocardiography (VD), cardiovascular magnetic resonance (CMR) (CBD), nuclear imaging (OG), and cardiac computed tomography (CT) (PMH) have selected the abstracts in their areas of expertise that were of most interest to them and are summarized in this bird's eye view from this ESC me...
Abstract
Cited 1 times since 2018 (0.2 per year)
source: EuropePMC
PloS one,
Volume 13, Issue 11, 15 3 2018, Pages e0207507
A stochastic simulation model to study respondent-driven recruitment.
Stein ML, Buskens V, van der Heijden PGM, van Steenbergen JE, Wong A, Bootsma MCJ, Kretzschmar MEE
Respondent-driven detection is a chain recruitment method used to sample contact persons of infected persons in order to enhance case finding. It starts with initial individuals, so-called seeds, who are invited for participation. Afterwards, seeds receive a fixed number of coupons to invite individuals with whom they had contact during a specific time period. Recruitees are then asked to do the same, resulting in successive waves of contact persons who are connected in one recruitment tree. How...
Abstract
Cited 1 times since 2018 (0.2 per year)
source: EuropePMC
JACC. Cardiovascular imaging,
Volume 12, Issue 4, 15 3 2018, Pages 759-760
Comparison of Insonation-Augmented Physical Examination With Standard Physical Examination in Detecting Severe Left-Sided Valve Disease.
Argulian E, Ramirez R, Hobson S, Bavishi C, Casso Dominguez A, Selby A, Talebi S, Moreno P, Ahmadi AA, Bax JJ, Narula J
Abstract
Cited 37 times since 2018 (5.8 per year)
source: EuropePMC
JACC. Cardiovascular imaging,
Volume 12, Issue 1, 15 3 2018, Pages 135-145
Transcatheter Aortic Heart Valves: Histological Analysis Providing Insight to Leaflet Thickening and Structural Valve Degeneration.
Sellers SL, Turner CT, Sathananthan J, Cartlidge TRG, Sin F, Bouchareb R, Mooney J, Nørgaard BL, Bax JJ, Bernatchez PN, Dweck MR, Granville DJ, Newby DE, Lauck S, Webb JG, Payne GW, Pibarot P, Blanke P, Seidman MA, Leipsic JA
Objectives: This study investigated processes causing leaflet thickening and structural valve degeneration (SVD). Background: Although transcatheter aortic valve replacement (TAVR) has changed the treatment of aortic stenosis, concerns remain regarding SVD, potentially related to valve thrombosis and thickening, based on studies using computed tomography (CT). Detailed histological analyses are provided to help attain insights into these processes. Methods: Explanted transcatheter heart valves (...
Abstract
Cited 6 times since 2018 (0.9 per year)
source: Scopus
JACC. Cardiovascular imaging,
Volume 12, Issue 1, 15 3 2018, Pages 216-217
Prognostic Value of Thoracic Aorta Calcification Burden in Patients Treated With TAVR.
Gegenava T, Vollema EM, Abou R, Goedemans L, van Rosendael A, van der Kley F, de Weger A, Ajmone Marsan N, Bax JJ, Delgado V
Abstract
Cited 19 times since 2018 (3 per year)
source: EuropePMC
European journal of human genetics : EJHG,
Volume 27, Issue 3, 12 2 2018, Pages 422-431
Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile.
Blauw LL, Noordam R, Soidinsalo S, Blauw CA, Li-Gao R, de Mutsert R, Berbée JFP, Wang Y, van Heemst D, Rosendaal FR, Jukema JW, Mook-Kanamori DO, Würtz P, Willems van Dijk K, Rensen PCN
According to the current dogma, cholesteryl ester transfer protein (CETP) decreases high-density lipoprotein (HDL)-cholesterol (C) and increases low-density lipoprotein (LDL)-C. However, detailed insight into the effects of CETP on lipoprotein subclasses is lacking. Therefore, we used a Mendelian randomization approach based on a genetic score for serum CETP concentration (rs247616, rs12720922 and rs1968905) to estimate causal effects per unit (µg/mL) increase in CETP on 159 standardized metabol...
Abstract
Cited 51 times since 2018 (8 per year)
source: EuropePMC
Journal of the American College of Cardiology,
Volume 73, Issue 4, 11 2 2018, Pages 387-396
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG, ODYSSEY OUTCOMES Committees and Investigators
Background: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. Objectives: This pre-specified analysis determined the extent to which alirocuma...
Abstract
Cited 16 times since 2018 (2.5 per year)
source: EuropePMC
Heart (British Cardiac Society),
Volume 105, Issue 10, 10 2 2018, Pages 790-796
Long-term outcome after atrial correction for transposition of the great arteries.
Couperus LE, Vliegen HW, Zandstra TE, Kiès P, Jongbloed MRM, Holman ER, Zeppenfeld K, Hazekamp MG, Schalij MJ, Scherptong RWC
Objective: This study assessed adult survival and morbidity patterns in patients who underwent atrial correction according to Mustard or Senning for transposition of the great arteries (TGA). Methods: In 76 adult patients with TGA (59% male) after atrial correction, long-term survival and morbidity were investigated in three periods: early (30 years postoperatively). Results: The Mustard technique was performed in 41 (54%) patients, and the Senning technique was performed in 35 (46%) patients ag...
Abstract
Cited 10 times since 2018 (1.6 per year)
source: EuropePMC
Langenbeck's archives of surgery,
Volume 403, Issue 8, 10 2 2018, Pages 999-1005
Safety and efficacy of subtotal or total parathyroidectomy for patients with secondary or tertiary hyperparathyroidism in four academic centers in the Netherlands.
van der Plas WY, Dulfer RR, Koh EY, Vogt L, Appelman-Dijkstra NM, Schepers A, Rotmans JI, Pol RA, van Ginhoven TM, Hoorn EJ, Nieveen van Dijkum EJM, Engelsman AF, de Borst MH, Kruijff S, Dutch Hyperparathyroidism Study Group (DHSG)
Purpose: Hyperparathyroidism (HPT) is a common abnormality in patients with end-stage renal disease (ESRD). Since the introduction of cinacalcet in 2004, a shift from surgery toward predominantly medical treatment has occurred. Surgery is thought to be associated with more complications than oral medication. The aim of this retrospective study was to evaluate 30-day outcomes and effectiveness of parathyroidectomy (PTx) in ESRD patients in the Netherlands. Methods: A national database containing...
Abstract
Cited 13 times since 2018 (2 per year)
source: EuropePMC
International journal of cardiology,
Volume 278, 10 2 2018, Pages 84-87
Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: Follow-up of a multicenter randomized controlled trial.
van Dissel AC, Winter MM, van der Bom T, Vliegen HW, van Dijk APJ, Pieper PG, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJM, Bouma BJ
Objectives: In the VAL-SERVE (Valsartan in Systemic Right Ventricle) trial, three-year valsartan treatment improved systemic ventricular function only in symptomatic patients with congenitally or with an atrial switch corrected transposition of the great arteries. The aim of the current study was to investigate the longer-term clinical outcomes after valsartan treatment. Methods: From 2006 to 2009, 88 adults were randomly allocated 1:1 to either valsartan or placebo for three consecutive years....
Abstract
Cited 3 times since 2018 (0.5 per year)
source: EuropePMC
Anatomical record (Hoboken, N.J. : 2007),
Volume 302, Issue 1, 9 2 2018, Pages 83-92
Disruption of RHOA-ROCK Signaling Results in Atrioventricular Block and Disturbed Development of the Putative Atrioventricular Node.
Kelder TP, Vicente-Steijn R, Poelmann RE, Schalij MJ, Deruiter MC, Jongbloed MRM, Gittenberger-de Groot AC
The RHOA-ROCK signaling pathway is involved in numerous developmental processes, including cell proliferation, differentiation and migration. RHOA is expressed in the atrioventricular node (AVN) and altered expression of RHOA results in atrioventricular (AV) conduction disorders in mice. The current study aims to detect functional AVN disorders after disturbing RHOA-ROCK signaling in chicken embryos. RHOA-ROCK signaling was inhibited chemically by using the Rho-kinase inhibitor compound Y-27632...
Abstract
Cited 1275 times since 2018 (200.7 per year)
source: EuropePMC
The New England journal of medicine,
Volume 379, Issue 22, 7 1 2018, Pages 2097-2107
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators
Background: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had a...
Abstract
